Aratana Therapeutics Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
Aratana Therapeutics (PETX) Misses Q1 EPS by 10c
May 5, 2016 4:34 PM EDTAratana Therapeutics (NASDAQ: PETX) reported Q1 EPS of ($0.52), $0.10 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $172 thousand versus the consensus estimate of $140 thousand.
For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.
... More